Log in

NASDAQ:VBLT - Vascular Biogenics Stock Price, Forecast & News

$1.37
-0.06 (-4.20 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$1.30
Now: $1.37
$1.45
50-Day Range
$1.13
MA: $1.39
$1.57
52-Week Range
$0.93
Now: $1.37
$1.90
Volume110,647 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:VBLT
Previous SymbolNASDAQ:VBLX
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees39
Next Earnings Date3/26/2020 (Estimated)
OptionableOptionable

Receive VBLT News and Ratings via Email

Sign-up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter.


Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd (NASDAQ:VBLT) announced its quarterly earnings results on Thursday, November, 14th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.14). The biopharmaceutical company earned $0.08 million during the quarter, compared to analyst estimates of $0.24 million. View Vascular Biogenics' Earnings History.

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Vascular Biogenics.

What price target have analysts set for VBLT?

5 analysts have issued 12 month price objectives for Vascular Biogenics' shares. Their forecasts range from $2.00 to $3.25. On average, they expect Vascular Biogenics' share price to reach $2.75 in the next year. This suggests a possible upside of 100.7% from the stock's current price. View Analyst Price Targets for Vascular Biogenics.

What is the consensus analysts' recommendation for Vascular Biogenics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vascular Biogenics.

What are Wall Street analysts saying about Vascular Biogenics stock?

Here are some recent quotes from research analysts about Vascular Biogenics stock:
  • 1. According to Zacks Investment Research, "Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. " (1/28/2020)
  • 2. Chardan Capital analysts commented, "We understand the colon cancer trial will be a single- arm open label design, providing the possibility of an early look at efficacy signals, with data anticipated in 2020. We expect more details on these programs as the GBM and colon cancer trials begin." (5/16/2019)

Has Vascular Biogenics been receiving favorable news coverage?

Media coverage about VBLT stock has trended extremely negative on Sunday, InfoTrie reports. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vascular Biogenics earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Vascular Biogenics.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 52,500 shares, an increase of 21.2% from the January 15th total of 43,300 shares. Based on an average daily trading volume, of 81,600 shares, the short-interest ratio is currently 0.6 days. Currently, 0.2% of the shares of the stock are short sold. View Vascular Biogenics' Current Options Chain.

What other stocks do shareholders of Vascular Biogenics own?

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the folowing people:
  • Prof. Dror Harats, CEO & Director (Age 62)
  • Mr. Amos Ron, CFO & Company Sec. (Age 64)
  • Dr. Erez Feige, VP of Bus. Operations (Age 45)
  • Dr. Eyal Breitbart, VP of Research & Operations (Age 52)
  • Dr. Naamit Sher, VP of Drug Devel. & Regulatory Affairs (Age 65)

Who are Vascular Biogenics' major shareholders?

Vascular Biogenics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.10%).

Which major investors are buying Vascular Biogenics stock?

VBLT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy shares of Vascular Biogenics?

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $1.37.


MarketBeat Community Rating for Vascular Biogenics (NASDAQ VBLT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  282 (Vote Underperform)
Total Votes:  534
MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote "Outperform" if you believe VBLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: Most Volatile Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel